David A. Siegel I Mab Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in I Mab stock. As of the latest transaction made, Two Sigma Advisers, LP holds 576,600 shares of IMAB stock, worth $628,494. This represents 0.0% of its overall portfolio holdings.
Number of Shares
576,600
Previous 617,100
6.56%
Holding current value
$628,494
Previous $1.15 Million
16.13%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding IMAB
# of Institutions
41Shares Held
15.8MCall Options Held
3KPut Options Held
1.9K-
Hhlr Advisors, Ltd. Grand Cayman, E96.91MShares$7.53 Million0.3% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$4.54 Million3.04% of portfolio
-
Boothbay Fund Management, LLC New York, NY1.38MShares$1.5 Million0.07% of portfolio
-
Two Sigma Investments, LP New York, NY478KShares$521,5010.0% of portfolio
-
International Biotechnology Trust PLC London, X0310KShares$338,4430.14% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $90.6M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...